Global Sarcopenia Treatment Market - Industry Trends and Forecast to 2030

Global Sarcopenia Treatment Market - Industry Trends and Forecast to 2030

The global sarcopenia treatment market is expected to reach USD 4,043,993.94 thousand by 2030 from USD 2,770,500.00 thousand in 2022, growing at a CAGR of 4.9% in the forecast period of 2023 to 2030.
Market Segmentation
Global Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest Of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific, Brazil, Argentina, and Rest Of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain, and Rest Of Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Global Sarcopenia Treatment Market Dynamics

Driver
• Rising prevalence of sarcopenia

Restraint

• Lack of standardized diagnosis

Opportunity

• Strategic initiatives by key market players

Market Players

Some of the key market players operating in the global sarcopenia treatment market are listed below:

• Abbott,
• Nestlé Health Science (A subsidiary of Nestlé S.A.),
• Novartis AG

• Sanofi
• Haleon Group of Companies
• BASF SE
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• BioThrive Sciences.
• Wellona Pharma
• The Vitamin Company India
• Biogen SA
• Healing Pharma India Pvt. Ltd
• Others